Filson Simon A, Keren Aviad, Goldstein Nyra, Ullmann Yehuda
Department of Plastic Surgery, Rambam Health Care Centre, Haifa, Israel.
Plast Reconstr Surg Glob Open. 2016 Jul 15;4(7):e806. doi: 10.1097/GOX.0000000000000821. eCollection 2016 Jul.
Fat grafting is an increasingly popular method of augmentation/reconstruction of soft tissue defects. However, the clinical unpredictability and high resorption rates of the grafts remain problematic. Cellular stress from the harvest and the ensuing ischemic episode may be the cause of this. Cellular stress activates the p38 mitogen-activated protein kinase (MAPK) signaling pathway. In response to cellular stress, the p38 pathway can lead to apoptosis and can negatively regulate cell proliferation. Inhibition of p38 in ex vivo experiments has been shown to promote the expansion of human cord blood hematopoietic stem cell and improve the adipogenesis process through its upstream regulator, Shp2. Because of its wide-ranging cell regulation and antiinflammatory properties, large-scale clinical trials using p38 inhibitors are also currently being performed, especially for therapeutic effect in chronic obstructive pulmonary disease and asthma. The rationale for our study was that the treatment of fat grafts with p38 inhibitor would (a) prevent apoptosis of adipose-derived stem cells in the fat grafts, (b) increase adipose-derived stem cells proliferation, and (c) stimulate the release of several angiogenic factors and promote revascularization.
Clinical and histological testing was performed on 5 fat-transplanted (1 mL) CD-1 nude mice compared with the test group of 5 mice, which were injected with a p38 MAPK inhibitor at 1, 3, 6, and 9 days after the fat transplantation.
The weights and volumes of the control group grafts were significantly higher than those of the p38 MAPK inhibitor-treated grafts. Average volume resorption was 36% in the control group and 92% in the test group. Histological evaluation of the grafts revealed significantly improved integration, with a significant reduction of fibrosis and inflammation in the control group versus the treated group.
This preliminary study suggests that as opposed to our hypothesis, inhibition of p38 significantly increases fat graft resorption. The dramatic effects observed in our study may suggest that p38 may act differently on the numerous cell types that constitute the fat graft, and further investigation is necessary.
脂肪移植是一种越来越流行的软组织缺损增大/重建方法。然而,移植物的临床不可预测性和高吸收率仍然是个问题。采集过程中的细胞应激以及随之而来的缺血事件可能是其原因。细胞应激会激活p38丝裂原活化蛋白激酶(MAPK)信号通路。响应细胞应激时,p38通路可导致细胞凋亡,并能对细胞增殖产生负调控。体外实验表明,抑制p38可通过其上游调节因子Shp2促进人脐带血造血干细胞的扩增,并改善脂肪生成过程。由于其广泛的细胞调节和抗炎特性,目前也正在进行使用p38抑制剂的大规模临床试验,特别是针对慢性阻塞性肺疾病和哮喘的治疗效果。我们研究的理论依据是,用p38抑制剂处理脂肪移植物将(a)防止脂肪移植物中脂肪来源干细胞的凋亡,(b)增加脂肪来源干细胞的增殖,以及(c)刺激几种血管生成因子的释放并促进血管再生。
对5只接受脂肪移植(1毫升)的CD-1裸鼠进行临床和组织学检测,并与5只在脂肪移植后第1、3、6和9天注射p38 MAPK抑制剂的小鼠组成的试验组进行比较。
对照组移植物的重量和体积显著高于p38 MAPK抑制剂处理组的移植物。对照组的平均体积吸收率为36%,试验组为92%。移植物的组织学评估显示,整合情况显著改善,与处理组相比,对照组的纤维化和炎症明显减少。
这项初步研究表明,与我们的假设相反,抑制p38会显著增加脂肪移植物的吸收率。我们研究中观察到的显著效果可能表明,p38可能对构成脂肪移植物的多种细胞类型有不同作用,因此有必要进一步研究。